Literature DB >> 21888265

Proton therapy for prostate cancer.

Bradford Hoppe1, Randal Henderson, William M Mendenhall, Romaine C Nichols, Zuofeng Li, Nancy P Mendenhall.   

Abstract

Proton therapy has been used in the treatment of cancer for over 50 years. Due to its unique dose distribution with its spread-out Bragg peak, proton therapy can deliver highly conformal radiation to cancers located adjacent to critical normal structures. One of the important applications of its use is in prostate cancer, since the prostate is located adjacent to the rectum and bladder. Over 30 years of data have been published on the use of proton therapy in prostate cancer; these data have demonstrated high rates of local and biochemical control as well as low rates of urinary and rectal toxicity. Although before 2000 proton therapy was available at only a couple of centers in the United States, several new proton centers have been built in the last decade. With the increased availability of proton therapy, research on its use for prostate cancer has accelerated rapidly. Current research includes explorations of dose escalation, hypofractionation, and patient-reported quality-of-life outcomes. Early results from these studies are promising and will likely help make proton therapy for the treatment of prostate cancer more cost-effective.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21888265

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  6 in total

1.  Acute toxicity of image-guided hypofractionated proton therapy for localized prostate cancer.

Authors:  Koichiro Nakajima; Hiromitsu Iwata; Hiroyuki Ogino; Yukiko Hattori; Shingo Hashimoto; Mikiko Nakanishi; Toshiyuki Toshito; Yukihiro Umemoto; Shoichiro Iwatsuki; Yuta Shibamoto; Jun-Etsu Mizoe
Journal:  Int J Clin Oncol       Date:  2017-11-02       Impact factor: 3.402

2.  A case-matched study of toxicity outcomes after proton therapy and intensity-modulated radiation therapy for prostate cancer.

Authors:  Penny Fang; Rosemarie Mick; Curtiland Deville; Stefan Both; Justin E Bekelman; John P Christodouleas; Thomas J Guzzo; Zelig Tochner; Stephen M Hahn; Neha Vapiwala
Journal:  Cancer       Date:  2014-11-25       Impact factor: 6.860

Review 3.  Charged particle therapy--optimization, challenges and future directions.

Authors:  Jay S Loeffler; Marco Durante
Journal:  Nat Rev Clin Oncol       Date:  2013-05-21       Impact factor: 66.675

4.  A Web application for the management of clinical workflow in image-guided and adaptive proton therapy for prostate cancer treatments.

Authors:  Daniel Yeung; Peter Boes; Meng Wei Ho; Zuofeng Li
Journal:  J Appl Clin Med Phys       Date:  2015-05-08       Impact factor: 2.102

5.  Patient-Reported Quality of Life in Men with Transurethral Resection of the Prostate Undergoing Proton Therapy for Management of Prostate Cancer.

Authors:  Derek T Lee; Nancy P Mendenhall; Tamara L Smith; Christopher G Morris; Romaine C Nichols; Curtis Bryant; Randal H Henderson; William M Mendenhall; Joseph Costa; Christopher R Williams; Zuofeng Li; Bradford S Hoppe
Journal:  Int J Part Ther       Date:  2016

6.  Proton beam irradiation stimulates migration and invasion of human U87 malignant glioma cells.

Authors:  Alexander Zaboronok; Tomonori Isobe; Tetsuya Yamamoto; Eisuke Sato; Kenta Takada; Takeji Sakae; Hideo Tsurushima; Akira Matsumura
Journal:  J Radiat Res       Date:  2013-11-01       Impact factor: 2.724

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.